OncoMatch/Clinical Trials/NCT06015022
EGCG for Hepatocellular Carcinoma Chemoprevention
Is NCT06015022 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Epigallocatechin gallate (EGCG) for cirrhosis, liver.
Treatment: Epigallocatechin gallate (EGCG) — This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: HLA-B wild-type
Absence of HLA-B*35:01
Prior therapy
Cannot have received: (EGCG)
Prior or ongoing use of EGCG
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate renal function
Liver function
Adequate hepatic function; No active hepatic decompensation
Adequate hematologic, hepatic, and renal function; No active hepatic decompensation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06015022 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Does this trial require HLA-B?
Yes, HLA-B wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify